

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/520,989	01/10/2005	Thomas Antkowiak	P01072US2A 5203		
7590 06/21/2006 Chief Intellectual Property Counsel Bridgestone Americas Holding Inc 1200 Firestone Parkway			EXAMINER		
			TESKIN, FRED M		
			ART UNIT	PAPER NUMBER	
Akron, OH 4			1713		
			DATE MAILED: 06/21/200	DATE MAILED: 06/21/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/520,989	ANTKOWIAK ET AL.			
Office Action Summary	Examiner	Art Unit			
	Fred M. Teskin	1713			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period was realiure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on 2a) ☐ This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-17 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) 2 is/are allowed. 6) Claim(s) 1.3.5,6,8,12,13 and 15 is/are rejected. 7) Claim(s) 4,7,9-11,14,16 and 17 is/are objected. 8) Claim(s) are subject to restriction and/or. Application Papers 9) The specification is objected to by the Examine. 10) The drawing(s) filed on is/are: a) access that any objection to the objection.	vn from consideration. to. election requirement. r. epted or b) objected to by the B	•			
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	jected to. See 37 CFR 1.121(d).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 053105.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Application/Control Number: 10/520,989

Art Unit: 1713

The preliminary amendment of January 10, 2005 having been entered, claims 1-17 are currently pending and under examination.

The disclosure is objected to because of the following informalities: the term "-4-methlpiperazine" is misspelled at page 5, line 16.

Appropriate correction is required.

Claims 5 and 12 are objected to because of the following informalities: the "or" connector should be relocated between the final two functional species, i.e., immediately before "-perhydroindole". Appropriate correction is required.

Claims 10 and 17 are objected to because of the following informalities: the term "ele[c]trophile" is misspelled (see the final line of each claim). Appropriate correction is required.

Claims 5, 6, 8, 12, 13 and 15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. More specifically, the following grounds for indefiniteness apply to the indicated claims.

(A) Claims 5 and 12 are indefinite as it is unclear whether the parenthetical expression "(or –perhydroazepine)" is intended to be synonymous with "-hexamethyleneimine" or further restrictive thereof. In the former case, the expression is

mere surplusage to the claims and should be deleted. As the claims are now drafted, the presence of the expression creates uncertainty as to the scope of the claims.

- (B) Claims 6 and 8 respectively recite the limitations "the cyclic-amino functionalized styryl compound" and "the cyclic amine compound". Each limitation lacks proper antecedent basis from claim 1. In this regard, note that claim 1 provides no precedent for "cyclic-amino" functionality or a "cyclic amine" compound.
- (C) Claims 13 and 15 also recite the limitations "the cyclic-amino functionalized styryl compound" and "the cyclic amine compound", respectively, which limitations lack proper antecedent basis from claim 3.
- (D) Claims 8 and 15 are incomplete, hence indefinite, due to omission of a bond line from the "cyclic" amine structure depicted in each claim. *Cf.*, formula (III) as shown in original claim 8. Appropriate correction is required.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1 and 3 are rejected under 35 U.S.C. 102(b) as being anticipated by any one of Morrison et al, Strecker and Vitus et al.

The references each disclose an anionic polymerization initiator prepared by reacting a specific organolithium compound (sec-butyllithium) with divinylbenzene under

Application/Control Number: 10/520,989

Art Unit: 1713

reaction conditions so as to form an adduct, and polymer preparation using the adduct so formed. See Morrison et al, Examples 1 (col. 6, II. 45+) and 11; Strecker, Example 1 (col. 4, II. 50+); and Vitus et al, Examples 1 (col. 6, line 34 to col. 7, line 5) and 7.

Claims 1 and 3 broadly call for preparing the initiator by combining a "functionalized styryl compound" and an "organolithium compound". Examiner considers the divinylbenzene used in preparing the prior art initiators to qualify as a *vinyl-functionalized* styryl compound, in that the vinyl groups participate in the addition reaction as detailed at, for example, column 4, lines 55-65 of Morrison et al.

As such, the cited art is seen to describe the recited process of "combining a functionalized styryl compound and an organolithium compound" to prepare an initiator, and the recited step of polymerizing monomer therewith. Accordingly, claims 1 and 3 are deemed to lack novelty.

The prior art made of record and not relied upon is considered pertinent to applicants' disclosure.

Trepka et al is pertinent to the preparation of polymerization initiators by reacting a halo- or thio-phenol with an alkyllithium compound.

Claim 2 is allowable on the present record. An anionic polymerization initiator defined as per the formula (I) is not taught nor fairly suggested in the available prior art.

Art Unit: 1713

Claims 4, 7, 9, 11, 14 and 16 are objected to as being dependent on a rejected base claim but would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claim.

Any inquiry concerning this communication should be directed to Examiner F. M. Teskin whose telephone number is (571) 272-1116. The examiner can normally be reached on Monday through Thursday from 7:00 AM - 4:30 PM, and can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu, can be reached on (571) 272-1114. The appropriate fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

FMTeskin/06-15-06

FRED TESKIN
PRIMARY EXAMINER